Home > Insider Trading > Filing (0001104659-13-084849)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	Pharmaceutical Preparations (2834)	263931704

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1270734	Deepika Pakianathan	Delphi Ventures, 3000 Sand Hill Rd, Bldg 1, Ste 135 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-12	1,773,318	$0.00	1,773,318	No	4	C	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2013-11-12	17,315	$0.00	17,315	No	4	C	Indirect	By Delphi BioInvestments VIII, L.P.
Common Stock	Acquisiton	2013-11-12	309,478	$16.00	2,082,796	No	4	P	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2013-11-12	3,022	$16.00	20,337	No	4	P	Indirect	By Delphi BioInvestmentsVIII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Delphi Ventures VIII, L.P.
No	4	C	Indirect	By Delphi BioInvestments VIII, L.P.
No	4	P	Indirect	By Delphi Ventures VIII, L.P.
No	4	P	Indirect	By Delphi BioInvestmentsVIII, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-11-12	1,500,500	$0.00	1,500,500	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-11-12	14,652	$0.00	14,652	$0.00
Common Stock	Series B-1 Convertible Preferred Stock	Disposition	2013-11-12	272,818	$0.00	272,818	$0.00
Common Stock	Series B-1 Convertible Preferred Stock	Disposition	2013-11-12	2,663	$0.00	2,663	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Represents the total number of shares received upon conversion of shares of the Issuer's Series B Convertible Preferred Stock (the "Series B Shares") and Series B-1 Convertible Preferred Stock (the "Series B-1 Shares", and together with the Series B Shares, collectively, the "Preferred Shares").
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein.
Effective upon closing of the Issuer's initial public offering of its Common Stock, the Preferred Shares automatically converted at a ratio of 1-for-3.3 into the number of shares of Common Stock shown in column 7. The Preferred Shares had no expiration date.